DGIdb - TANDUTINIB Drug Record

TANDUTINIB chembl:CHEMBL124660 Antineoplastic

Alternate Names:

TANDUTINIB
MLN-0518
MLN-518
CT-53518
CT53518

Drug Info:

FDA Approval	not approved
Drug Class	small molecule
Drug Indications	antineoplastic agent
Drug Class	Kinase Inhibitors

(3 More Sources)

Publications:

Clark et al., 2004, Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518., Blood
Pandey A et al., 2002, Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family., J Med Chem
Uras et al., 2016, Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6., Blood
Kelly et al., 2002, CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)., Cancer Cell

TANDUTINIB FLT3

Interaction Score: 0.73

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name tandutinib, MLN-518

Mechanism of Interaction Tyrosine-protein kinase receptor FLT3 inhibitor

PMIDs:
15256420 12166950 27099147 12124172

Sources:
DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC
TANDUTINIB ITK

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TANDUTINIB ACVR1

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TANDUTINIB KIT

Interaction Score: 0.3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Stem cell growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
DTC MyCancerGenome ChemblInteractions
TANDUTINIB PDGFRB

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

PMIDs:
None found

Sources:
DTC MyCancerGenome ChemblInteractions
TANDUTINIB NTRK3

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TANDUTINIB PDGFRA

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DTC MyCancerGenome
TANDUTINIB CSF1R

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DTC
TANDUTINIB CLK4

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TANDUTINIB FLT4

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: TANDUTINIB
- Version: 20-Jun-2017
Alternate Names:

MLN518 Development Name

CT53518 Development Name

TANDUTINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: TANDUTINIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

DTC: TANDUTINIB

Version: 02-September-2020

Alternate Names:

CHEMBL124660 ChEMBL Drug ID

Drug Info:

Publications:

Pandey A et al., 2002, Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family., J Med Chem

JAX-CKB: Tandutinib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Uras et al., 2016, Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6., Blood

Kelly et al., 2002, CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)., Cancer Cell

CIViC: TANDUTINIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Clark et al., 2004, Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518., Blood
ChemblDrugs: chembl:CHEMBL124660
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL124660
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Novel drug target	Established target
Trial Name	tandutinib, MLN-518
Mechanism of Interaction	Tyrosine-protein kinase receptor FLT3 inhibitor

Mechanism of Interaction	Stem cell growth factor receptor inhibitor
Direct Interaction	yes

Direct Interaction	yes
Mechanism of Interaction	Platelet-derived growth factor receptor beta inhibitor

MLN518	Development Name
CT53518	Development Name
TANDUTINIB	Generic Name

TANDUTINIB Drug Record

TANDUTINIB chembl:CHEMBL124660 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name tandutinib, MLN-518 Mechanism of Interaction Tyrosine-protein kinase receptor FLT3 inhibitor

PMIDs: 15256420 12166950 27099147 12124172

Sources: DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Stem cell growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: DTC MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

PMIDs: None found

Sources: DTC MyCancerGenome ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: DTC MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

MyCancerGenome: TANDUTINIB

Alternate Names: MLN518 Development Name CT53518 Development Name TANDUTINIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: TANDUTINIB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class small molecule FDA Approval not approved

Publications:

DTC: TANDUTINIB

Alternate Names: CHEMBL124660 ChEMBL Drug ID

Drug Info:

Publications: Pandey A et al., 2002, Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family., J Med Chem

JAX-CKB: Tandutinib

Alternate Names:

Drug Info:

Publications: Uras et al., 2016, Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6., Blood Kelly et al., 2002, CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)., Cancer Cell

CIViC: TANDUTINIB

Alternate Names:

Drug Info:

Publications: Clark et al., 2004, Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518., Blood

ChemblDrugs: chembl:CHEMBL124660

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL124660

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name tandutinib, MLN-518

Mechanism of Interaction Tyrosine-protein kinase receptor FLT3 inhibitor

PMIDs:
15256420 12166950 27099147 12124172

Sources:
DTC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Stem cell growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
DTC MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

PMIDs:
None found

Sources:
DTC MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
DTC MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

MLN518 Development Name

CT53518 Development Name

TANDUTINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Alternate Names:

CHEMBL124660 ChEMBL Drug ID

Publications:

Pandey A et al., 2002, Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family., J Med Chem

Publications:

Uras et al., 2016, Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6., Blood

Kelly et al., 2002, CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)., Cancer Cell

Publications:

Clark et al., 2004, Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518., Blood